Monoclonal antibodies lock down SARS-CoV-2 spike

Hsiang-Chi Huang; Davide Angeletti

doi:10.1016/j.it.2023.09.006

Monoclonal antibodies lock down SARS-CoV-2 spike

Trends Immunol. 2023 Nov;44(11):874-876. doi: 10.1016/j.it.2023.09.006. Epub 2023 Oct 5.

Authors

Hsiang-Chi Huang¹, Davide Angeletti²

Affiliations

¹ Department of Microbiology and Immunology, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden; Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden; Wallenberg Center for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.
² Department of Microbiology and Immunology, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden; SciLifeLab, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden. Electronic address: davide.angeletti@gu.se.

PMID: 37805348
DOI: 10.1016/j.it.2023.09.006

Abstract

SARS-CoV-2 rapidly accumulated mutations in its immunodominant receptor-binding domain (RBD), rendering all clinically authorized monoclonal antibodies (mAbs) ineffective. Liu et al. unveil potent human mAbs that neutralize all tested SARS-CoV-2 variants by locking the Spike protein RBD in a downward conformation, thus inhibiting receptor engagement.

Keywords: Omicron; SARS-CoV-2; broadly neutralizing antibody; cryo-EM; monoclonal antibodies.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antibodies, Monoclonal / therapeutic use
Antibodies, Neutralizing
Antibodies, Viral
COVID-19*
Communicable Disease Control
Humans
Immunodominant Epitopes
SARS-CoV-2

Substances

Antibodies, Monoclonal
Immunodominant Epitopes
Antibodies, Viral
Antibodies, Neutralizing

Supplementary concepts

SARS-CoV-2 variants